320 West 37th Street
6th Floor
New York, NY 10018
United States
(917) 580-3099
https://immunovant.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 164
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Dr. Frank M. Torti M.B.A., M.D. | Executive Chairperson of the Board | 92,5k | N/D | 1979 |
Dr. Peter Salzmann M.B.A., M.D. | CEO & Director | 1,02M | N/D | 1968 |
Ms. Eva Renee Barnett M.B.A. | Chief Financial Officer | 871,07k | N/D | 1981 |
Dr. William L. Macias M.D., Ph.D. | Chief Medical Officer | 719,88k | N/D | 1959 |
Dr. Jay S. Stout Ph.D. | Chief Technology Officer | N/D | N/D | 1964 |
Dr. Chau Cheng M.B.A., Ph.D. | Vice President of Investor Relations | N/D | N/D | N/D |
Mr. Mark S. Levine | Chief Legal Officer & Corporate Secretary | N/D | N/D | 1973 |
Ms. Lauren Schrier M.B.A. | Vice President of Marketing | N/D | N/D | N/D |
Ms. Christine Blodgett | Vice President of Human Resources | N/D | N/D | N/D |
Dr. Julia G. Butchko Ph.D. | Chief Development Officer | 531k | N/D | 1971 |
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
L'ISS Governance QualityScore di Immunovant, Inc. al 1 maggio 2024 è 10. I criteri di valutazione fondamentali sono revisione: 7; Consiglio di Amministrazione: 10; diritti degli azionisti: 10; retribuzione: 8.